Investor Chamath Palihapitiya warned that advancing AI technology might eventually hack Bitcoin's hashing algorithm, potentially crashing its price to zero. He highlighted risks like privacy breaches and AI-enabled hacking that could expose wallets and manipulate the market. Palihapitiya no longer holds Bitcoin directly due to security concerns, preferring exposure through Bitcoin ETFs, which simplify investment and reduce risks. This warning raises concerns about Bitcoin's long-term security amid evolving AI threats.
Billionaire investor Chamath Palihapitiya's warning about Bitcoin and AI hacking comes as a backdrop for cryptocurrency market data. For readers following major cryptocurrencies, here is Pluang's market snapshot as of Oct 24, 2026 01:31 WIB: 43 of 50 major cryptocurrencies rose today. Yearn (YFI) traded at Rp39.837.602 with a 3.00% gain, while Uniswap (UNI) rose 2.60% to Rp129.204, and The Sandbox (SAND) fell 2.60% to Rp942.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
